Study: Aloe Vera Compound Shows Early Promise Against Alzheimer’s Enzymes

A new study in the journal Current Pharmaceutical Analysis reports that beta‑sitosterol, a compound found in the common household plant aloe vera, showed strong binding in computer simulations to two brain enzymes — cholinesterase and butyrylcholinesterase — that break down the neurotransmitter acetylcholine, which is depleted in Alzheimer’s disease. Researchers at the University of Casablanca used molecular‑docking and related in‑silico tools and concluded beta‑sitosterol might act as a “dual inhibitor,” theoretically helping preserve acetylcholine in ways similar to existing symptom‑relief drugs. They also modeled its absorption and toxicity and report that, on paper, the compound appears well‑absorbed and unlikely to be toxic at therapeutic levels. But outside experts, including Christopher Weber of the Alzheimer’s Association, stress that the work is purely computational so far, has not been tested in animals or humans, and would not modify the underlying disease process even if it pans out. Weber cautions that over‑the‑counter aloe supplements have never been validated for dementia treatment, and says consumers should be skeptical of any therapeutic claims based solely on these early simulations.